Stop the clots, but at what cost? Pharmacoeconomics of dabigatran etexilate for the prevention of stroke in subjects with atrial fibrillation: a systematic literature review

Author： Marshall Sarah   Fearon Patricia   Dawson Jesse   Quinn Terence J  

Publisher： Informa Healthcare

ISSN： 1473-7167

Source： Expert Review of Pharmacoeconomics and Outcomes Research, Vol.13, Iss.1, 2013-02, pp. : 29-42

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation†

By Garnock-Jones Karly P.  

Drugs & Aging, Vol. 28, Iss. 5, 2011-05 ,pp. : 415-419

Adis International

Access to resources Recommend Favorite

Dabigatran Etexilate: A Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

By Garnock-Jones Karly P.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 1, 2011-02 ,pp. : 57-72

Adis International

Access to resources Recommend Favorite

Dabigatran Etexilate: A Pharmacoeconomic Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

By McKeage Kate  

PharmacoEconomics, Vol. 30, Iss. 9, 2012-09 ,pp. : 841-855

Adis International

Access to resources Recommend Favorite

Dabigatran etexilate: a dab hand for stroke prevention in AF

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 642, 2011-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Ximelagatran Cost Effectiveness for Stroke Prevention in Atrial Fibrillation

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 35, Iss. 4, 2005-12 ,pp. : 279-283

John Wiley & Sons Inc

Access to resources Recommend Favorite